FDA knocks back Mallinckrodt’s kidney drug terlipressin

Manufacturing problems seem to have scuppered Mallinckrodt’s hopes of bringing the first approved drug to market in the US for hepatorenal syndrome (HRS), a life-threatening condition that causes scarring and fluid build-up in the kidney, at least for now.